# Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

Source: https://onco.cc/trials/nct06959082/  
OnCo record `nct06959082` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by VSPharmTech Co.,Ltd., now recruiting.

## Summary

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer is a phase 2 interventional study registered as NCT06959082 by VSPharmTech Co.,Ltd., with 30 participants planned, started 2025-06-11 and due to reach its primary completion in 2027-12. Interventions recorded: VS-101, Cisplatin and Radiation.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06959082
- Phase: 2
- Setting: A Multi-center, Randomized, Open-label, Parallel-group, Phase 2 Study to Evaluate the Efficacy and Safety of VS-101 in Combination With Chemoradiotherapy (CRT) in Patients With Head and Neck Cancer
- Sponsor: VSPharmTech Co.,Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06959082: https://clinicaltrials.gov/study/NCT06959082

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct06959082.json